跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RIVASTIGMINE PATCH 15 - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RIVASTIGMINE PATCH 15
Authorized
STANDARD
RIVASTIGMINE PATCH 15
Pharmascience Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c0049737802d9fa9
Company
Pharmascience Inc
Type
Standard
Approval Details
Approval Id
c0049737802d9fa9
Drug Approval Canada Name
RIVASTIGMINE PATCH 15
Product Name
RIVASTIGMINE PATCH 15
Status
Dormant
Status Date
2024-07-31
Original Market Date
2021-04-15
Din
02479567
Drug Class
Human
Dosage Form
Patch
Route Of Administration
Transdermal
Schedule
Prescription
Ahfs
12:04.00
Atc Original
N06DA03 RIVASTIGMINE
Atc Name
n 06 da 03
Aig Number
0140521009
Company Name
Pharmascience Inc
Company Address
100, 6111 Royalmount Ave, Montreal, Quebec, Canada, H4P 2T4
Company Detail Path
/organization/pharmascience-inc
Company Information
Pharmaceutical Company Name
Pharmascience Inc
Country Name
Canada
Province Name
Quebec
City Name
montréal,quebec,country_ca
Address
6111 av Royalmount bureau 100
Active Ingredients
RIVASTIGMINE
13.3 MG / 24 HOUR
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c0049737802d9fa9
Type
Standard
Back to Health Canada Approvals